Company news

Zoetis Inc. news in 2025

Zoetis Inc.'s news releases, calls and decks from 2025, newest first.

View company

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

December 30, 2025

Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering

December 16, 2025

Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

December 15, 2025

Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

December 11, 2025

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

December 5, 2025

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

December 2, 2025

Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

November 26, 2025

Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 20, 2025

Zoetis to Host Innovation Webcast

November 19, 2025

Zoetis Announces Third Quarter 2025 Results

November 4, 2025

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

November 3, 2025

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

October 29, 2025

Zoetis Appoints Stephanie Tilenius to its Board of Directors

October 28, 2025

Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs

October 15, 2025

Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

October 10, 2025

Zoetis Declares Fourth Quarter 2025 Dividend

October 9, 2025

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

September 30, 2025

Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results

September 23, 2025

Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

September 12, 2025

Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 27, 2025

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

August 11, 2025

Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

August 5, 2025

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

July 1, 2025

Zoetis Releases 2024 Sustainability Progress Update

June 5, 2025

Dr. Mark Stetter Elected to Zoetis Board of Directors

May 22, 2025

Zoetis Declares Third Quarter 2025 Dividend

May 21, 2025

Zoetis to Participate in Upcoming Investor Conferences

May 15, 2025

Zoetis Announces First Quarter 2025 Results

May 6, 2025

Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

March 27, 2025

Calls in 2025

Decks in 2025